MTEP

3-((2-Methyl-4-thiazolyl)ethynyl)pyridine (MTEP) is a research drug that was developed by Merck & Co. as a selective allosteric antagonist of the metabotropic glutamate receptor subtype mGluR5. Identified through structure-activity relationship studies on an older mGluR5 antagonist MPEP,^[1] MTEP has subsequently itself acted as a lead compound for newer and even more improved drugs.^[2][3]

MTEP

Identifiers
IUPAC name 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine
CAS Number	329205-68-7 Y
PubChem CID	9794218
IUPHAR/BPS	3336
ChemSpider	7969985 N
UNII	XDA7P9K5S6
CompTox Dashboard (EPA)	DTXSID30430775
Chemical and physical data
Formula	C11H8N2S
Molar mass	200.26 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=NC(=CS1)C#CC2=CN=CC=C2
InChI InChI=1S/C11H8N2S/c1-9-13-11(8-14-9)5-4-10-3-2-6-12-7-10/h2-3,6-8H,1H3 N Key:NRBNGHCYDWUVLC-UHFFFAOYSA-N N
NY (what is this?)  (verify)

MTEP is both more potent and more selective than MPEP as a mGluR5 antagonist,^[4] and produces similar neuroprotective,^[5][6][7] antidepressant,^{[8][9][10][11]} analgesic,^[12][13] and anxiolytic effects but with either similar or higher efficacy depending on the test used.^{[14][15][16][17]}

MTEP also has similar efficacy to MPEP in reducing the symptoms of morphine withdrawal,^[18][19][20] and has anti-addictive effects in a variety of animal models, both reducing ethanol self-administration,^{[21][22][23][24]} and also decreasing the addictive effects of nicotine, cocaine and methamphetamine.^{[25][26][27][28][29]}

See also

• MPEP
• MFZ 10-7
• Fenobam